高初始剂量表面活性剂预防或治疗早产儿呼吸窘迫综合征。

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2025-04-28 DOI:10.1002/14651858.CD016180

Franciszek Borys, Greta Sibrecht, Aliyyah Mohammad Khuzaini, Michelle Fiander, Matteo Bruschettini, Roger F Soll

引用次数: 0

摘要

目的：这是Cochrane综述（干预）的一个方案。目的如下：评估与标准剂量相比，较高初始剂量表面活性剂对高危早产儿和有呼吸窘迫综合征的早产儿的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Higher initial doses of surfactant for the prevention or treatment of respiratory distress syndrome in preterm infants.

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of higher - compared with standard - initial doses of surfactant in high-risk preterm infants and preterm infants with respiratory distress syndrome.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.